Patient-derived tumour xenografts for breast cancer drug discovery

  1. Alejandra Bruna2
  1. 1Breast Cancer Functional Genomics, CRUK Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK
  2. 2Department of Oncology, University of Cambridge, Cambridge, UK
  1. Correspondence should be addressed to J W Cassidy or A Bruna; Email: john.cassidy{at} or alejandra.bruna{at}
  1. Figure 1

    High-throughput drug screen using patient-derived material. Figure 1 highlights high-throughput screening approaches using patient tumour material. (1) represents in vitro culture of tumour explants (for example as organoids/tumoroids). (2) represents the integrated PDTX:PDTC platform developed by our lab. In this strategy, patient tumour material is passaged and maintained in the murine host, and patient-derived tumour cells (PDTCs) are periodically dissociated for short-term ex vivo culture and high-throughput drug screens.

  2. Figure 2

    Biomarker discovery using PDTX models. Figure 2 highlights an unbiased approach for biomarker discovery. (1) a mixed cohort of PDTX models is screened with multiple compounds affecting different members of the same signalling pathway and are subsequently clustered based on responders and non-responders. Genomic correlates of drug response are computed before validation in vivo (2).

| Table of Contents